4′-fluoro nucleosides for the treatment of HCV
US-9211300-B2 · Dec 15, 2015 · US
US10092587B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10092587-B2 |
| Application number | US-201615389248-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 22, 2016 |
| Priority date | Jun 25, 2014 |
| Publication date | Oct 9, 2018 |
| Grant date | Oct 9, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to an antiviral composition comprising any one selected from the group consisting of chlorine, phosphocholine, cytidine triphosphate, CDP-choline, phosphorylcholine, and phosphatidylcholine. The antiviral composition is harmless to the human body and exhibits an excellent inhibitory effect on virus proliferation. Therefore, it can be applied to a pharmaceutical composition for preventing or treating viral diseases as well as a health functional food, a quasi-drug composition, and a feed composition for preventing or ameliorating viral diseases.
Opening claim text (preview).
The invention claimed is: 1. A method of enhancing antiviral activity in a subject infected by a virus, comprising administering an antiviral composition to the subject, wherein the virus belongs to the family picornaviridae and the composition comprises at least one substance involved in phosphatidyl synthesis pathway, selected from the following group: i) choline; ii) phosphocholine; iii) cytidine diphosphate-choline (CDP-choline); iv) phosphorylcholine; and v) phosphatidylcholine. 2. The method of claim 1 , wherein the composition further comprises cytidine triphosphate (CTP). 3. The method of claim 1 , wherein the virus is any one selected from the group consisting of rhinovirus, enterovirus, cardiovirus, aphthovirus , and hepatovirus. 4. The method of claim 3 , wherein the rhinovirus is any one selected from the group consisting of rhinovirus type 2, type 3, and type 5. 5. The method of claim 3 , wherein the enterovirus is coxsackievirus type A or coxsackievirus type B. 6. A method for treating a subject infected by a viral disease, comprising administrating an antiviral composition to the subject, wherein the virus belongs to the family picornaviridae and the composition comprises at least one substance involved in phosphatidyl synthesis pathway, selected from the following group: i) choline; ii) phosphocholine; iii) cytidine diphosphate-choline (CDP-choline); iv) phosphorylcholine; and v) phosphatidylcholine. 7. The method of claim 6 for treating a viral disease, wherein the viral disease comprises any one selected from the group consisting of cold, enteritis, hand-foot-mouth disease, viral meningitis, pneumonia, encephalitis, neurogenic pulmonary edema, conjunctivitis, encephalomyocarditis, myocarditis, hepatitis, poliomyelitis, paralysis, vesicular disease, myositis, pancreatitis, epidemic myalgia, herpangina, asthma, chronic obstructive pulmonary disease, sinusitis, and tympanitis. 8. The method of claim 6 for treating a viral disease, wherein the viral disease is a cold. 9. The method of claim 6 , wherein the composition further comprises cytidine triphosphate (CTP). 10. A method of enhancing antiviral activity in a subject, comprising administering an antiviral composition to the subject infected by a virus, wherein the virus is any one selected from the group consisting of rhinovirus type 2, rhinovirus type 3, rhinovirus type 5, coxsackievirus type A and coxsackievirus type B, and the composition comprises cytidine triphosphate (CTP).
Compounds containing phosphorus · CPC title
Sugars; Polysaccharides · CPC title
having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title
containing six-membered rings with nitrogen as a ring hetero atom · CPC title
Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.